Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD on Immune Nutrisoda

This article was originally published in The Tan Sheet

Executive Summary

PepsiAmericas subsidiary Ardea Beverages will discontinue a print advertisement for Immune Nutrisoda following a determination by the National Advertising Division that "the advertisement went beyond simple structure/function claims." The ad, which featured images of a can of the product and an airplane, stated "protection from seat 33b." Other claims in the ad included "Immune Nutrisoda doesn't just refresh you, it revitalizes you....It's full of the right stuff to help support your body's immune defenses." The images and statements in the spot "combine to convey a message that this product will do more than simply provide vitamins and minerals that will help to maintain a healthy immune system," NAD concludes in a Nov. 21 decision. Ardea "respectfully disagrees" with NAD's assessment, but says it will take the suggestions into consideration in planning future advertisements...

You may also be interested in...



Medtech Biggest Casualty In Swiss/EU Uncertainty As Worst Case Scenario Looms

Eighteen years of free trade threatens to crash, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.

Interview: OurCrowd CEO Jon Medved On Israel’s Medtech “Boomtown”

With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Topics

UsernamePublicRestriction

Register

PS099985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel